KEYNOTE-942 trial: 3 year update

At ASCO, Prof Jeffrey Weber presented the 3-year update of the KEYNOTE-942 trial. mRNA-4157 is an innovative, mRNA-based individualized neoantigen therapy designed to enhance endogenous antitumor T-cell responses by targeting unique patient-specific tumour mutations. In the phase 2 KEYNOTE-942 trial, patients with completely resected high-risk stage IIIB–IV cutaneous melanoma treated with mRNA-4157 in combination with pembrolizumab demonstrated significantly prolonged RFS and DMFS compared to those receiving pembrolizumab alone, with a median planned follow-up of 23 months. The updated analysis, with approximately three years of median follow-up, confirmed the durable and meaningful long-term benefits in RFS and DMFS for the combination therapy over pembrolizumab alone. A trend towards improved OS was also observed, but longer follow-up is needed to see a statistical difference between both treatment arms.
These findings highlight the potential of mRNA-4157 combined with pembrolizumab to provide substantial clinical benefits in high-risk melanoma patients.